English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduAs part of the COVID-19 International Research Team, researchers at the Johns Hopkins Kimmel Cancer Center, Children’s Hospital of Philadelphia, the University of Pittsburgh and Weill Cornell Medicine discovered a novel cause of cytokine storm — the extreme inflammatory response associated with increased risk of death in COVID-19 infection.
Tag: cytokine storm
Fighting COVID-19 With a Cancer Drug
Researchers at University of California San Diego show that a molecule which shuttles damaging inflammatory cells into cancer tumors also shuttles inflammatory cells into lung tissue infected with COVID-19 — and that the molecule can be suppressed with a repurposed cancer drug. The work represents a new approach to preventing irreversible organ damage in infectious diseases.
Mesenchymal stem cells and their derived exosomes for the treatment of COVID-19
Coronavirus disease 2019 (COVID-19) is an acute respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 infection typically presents with fever and respiratory symptoms, which can progress to
What really killed COVID-19 patients: it wasn’t a cytokine storm
Secondary bacterial infection of the lung (pneumonia) was extremely common in patients with COVID-19, affecting almost half the patients who required support from mechanical ventilation.
Research Unveils Paths to Stopping Cytokine Storms in COVID-19
New research from RUSH University reveals pathways to reducing organ injury caused by severe COVID-19 infection. What began as a study of how the common cold affected patients with certain types of kidney disease evolved to mitigating myocarditis, liver injury and severe kidney injury from COVID-19.
Exploring the Science of Acupuncture
Researchers have discovered neurons needed for acupuncture‘s anti-inflammatory response
AI Predicts How Patients with Viral Infections, Including COVID-19, Will Fare
UC San Diego School of Medicine researchers discovered gene expression patterns associated with pandemic viral infections, providing a map to help define patients’ immune responses, measure disease severity, predict outcomes and test therapies — for current and future pandemics.
Penn Medicine Researcher Awarded $1 Million to Expand COVID-19 Treatment Discovery Platform
David C. Fajgenbaum, MD, MBA, MSc, an assistant professor of Translational Medicine & Human Genetics and director of the Center for Cytokine Storm Treatment & Laboratory at the Perelman School of Medicine at the University of Pennsylvania, was awarded $1 million by the Parker Institute for Cancer Immunotherapy (PICI) to expand the scope of the COvid19 Registry of Off-label & New Agents (CORONA) project and build out his team to accelerate treatment identification for COVID-19.
Repurposed Arthritis Drug Did Not Significantly Improve Severe COVID-19 Pneumonia
A repurposed drug used to treat arthritis did not significantly improve the outcomes of patients with severe COVID-19 pneumonia. Tocilizumab did not significantly improve clinical status or mortality rate at 28 days for participants who received it compared to a placebo.
Researchers Find Impaired Mitochondrial and Metabolic Function in COVID-19 Patients
New research published ahead of print in the American Journal of Physiology-Cell Physiology explores the role of mitochondrial function and related metabolic changes in the inflammatory response seen in people with COVID-19, the disease caused by the SARS-CoV-2 virus. Dysfunction…
Study: Respiratory failure in COVID-19 usually not driven by cytokine storm
A study from researchers at Washington University School of Medicine in St. Louis and St. Jude Children’s Research Hospital in Memphis showed that, contrary to expectations, most people with severe COVID-19 do not suffer from unbridled inflammation. The findings suggest that anti-inflammatory therapies may not be helpful for most COVID-19 patients.
Fluvoxamine may prevent serious illness in COVID-19 patients
Researchers at Washington University School of Medicine in St. Louis have completed a clinical trial suggesting that the antidepressant drug fluvoxamine may help prevent deterioration in COVID-19 patients, making hospitalization less likely.
Research Team Discovers the Molecular Processes in Kidney Cells That Attract and Feed COVID-19
What about the kidneys make them a hotspot for COVID-19’s cytokine storm? A research team says it’s the presence of a protein found on specialized renal transport cells.
Criteria to predict cytokine storm in COVID-19 patients identified by Temple Researchers
Like a cold front that moves in, setting the stage for severe weather, coronavirus infection triggers showers of infection-fighting immune molecules – showers that sometimes escalate into a chaotic immune response known as a cytokine storm.
Protein that Keeps Immune System from Freaking Out Could Form Basis for New Therapeutics
Treatment with a peptide that mimics the naturally occurring protein GIV prevents immune overreaction and supports a mechanism critical for survival in mouse models of sepsis and colitis, according to a UC San Diego study.
Reproductive Hormone May Curb COVID-19 Inflammation, Prevent ‘Cytokine Storm’
Researchers have used “omics” data containing genetic profiles of drugs to identify the hormone oxytocin as a possible treatment for COVID-19, the disease caused by the novel coronavirus (SARS-CoV-2).
Researchers pivot from studying cancer and cystic fibrosis to launch trial of drug to fight COVID-19
The University of Kansas Medical Center announced today a trial exploring a drug intended to fight the cytokine storm common in COVID-19.
Quieting the Storm
A team of researchers led by neuroscientists at Harvard Medical School has successfully used acupuncture to tame cytokine storm in mice with systemic inflammation.
Drug that calms ‘cytokine storm’ associated with 45% lower risk of dying among COVID-19 patients on ventilators
Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be out of the hospital or off a ventilator one month after treatment, compared with those who didn’t receive the drug, according to a new observational study.
Individualized Treatment for COVID-19 Patients Should Be Based on Three Disease Phases
A new review details three distinct phases of COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, and urges medical professionals to consider an individualized treatment approach based on the disease phases and each patient’s symptoms. The review is published ahead of print in Physiological Reviews.